Recombinant Mouse Mtor Protein, His-tagged

• Cat.No.: Mtor-1798M
• Product Overview: Recombinant Mouse Mtor Protein (Ala2226-Val2488) with N-His tag was expressed in E. coli.

Specification

• Description: Enables protein serine/threonine kinase activity and ribosome binding activity. Involved in several processes, including 'de novo' pyrimidine nucleobase biosynthetic process; T-helper 1 cell lineage commitment; and neuronal action potential. Acts upstream of or within several processes, including heart development; positive regulation of cellular component biogenesis; and regulation of protein phosphorylation. Located in cytosol; dendrite; and nucleus. Part of TORC1 complex. Colocalizes with PML body. Is expressed in central nervous system; early conceptus; oocyte; respiratory system; and retina. Human ortholog(s) of this gene implicated in autosomal dominant polycystic kidney disease; kidney angiomyolipoma; lung disease (multiple); prostate cancer; and type 2 diabetes mellitus. Orthologous to human MTOR (mechanistic target of rapamycin kinase).
• Source: E. coli
• Species: Mouse
• Tag: His
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 33.4 kDa
  Accurate Molecular Mass: 33 kDa
• Protein length: Ala2226-Val2488
• Purity: > 90%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Storage Buffer: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
• Reconstitution: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Gene Information

• Gene Name: Mtor mechanistic target of rapamycin (serine/threonine kinase) [ Mus musculus (house mouse) ]
• Official Symbol: Mtor
• Synonyms: MTOR; mechanistic target of rapamycin (serine/threonine kinase); serine/threonine-protein kinase mTOR; rapamycin target protein 1; angiopoietin-like factor CDT6; mammalian target of rapamycin; FKBP-rapamycin-associated protein FRAP; FKBP-rapamycin associated protein (FRAP); FKBP12-rapamycin complex-associated protein; FK506 binding protein 12-rapamycin associated protein 1; FK506-binding protein 12-rapamycin complex-associated protein 1; FRAP; flat; FRAP2; Frap1; RAFT1; RAPT1; AI327068; 2610315D21Rik; MGC118056
• Gene ID: 56717
• mRNA Refseq: NM_020009
• Protein Refseq: NP_064393
• UniProt ID: Q9JLN9

Reviews

12/27/2020

With its reliable performance and consistent results, the MTOR protein provides researchers with the confidence and accuracy required for successful experimentation.

02/16/2019

The MTOR protein stands out as a protein of exceptional quality, perfectly suited to meet the experimental needs of researchers.

12/01/2016

One remarkable aspect of working with the MTOR protein is the excellent technical support provided by its manufacturer.

Q&As

How does dysregulation of the MTOR pathway contribute to the development of certain diseases?

Dysregulation of the MTOR pathway has been linked to various diseases, including cancer, metabolic disorders, and neurological conditions.

How does the MTOR pathway influence the response to immunotherapy in cancer treatment?

Activation of the MTOR pathway can impair the response to immunotherapy by promoting immunosuppressive mechanisms within the tumor microenvironment.

What are the mechanisms through which the MTOR pathway contributes to drug resistance in cancer?

The enhancement of drug efflux pumps, increased repair of DNA damage, and the promotion of cancer stem cell survival are some of the mechanisms by which the MTOR pathway contributes to drug resistance.

How can the knowledge of the MTOR pathway be leveraged to develop novel cancer therapies?

Understanding the molecular mechanisms of the MTOR pathway can aid in the development of targeted therapies that specifically inhibit its activity, thereby improving cancer treatment outcomes.

What are the implications of MTOR pathway dysregulation in metabolic disorders?

Dysregulation of the MTOR pathway has been linked to metabolic disorders such as obesity, diabetes, and insulin resistance, highlighting its role in metabolic homeostasis.